ResQ Pharma
Glenview, US · United States corporation · 1 known investors
Find your way into ResQ Pharma
408 people in our graph share verified history with the ResQ Pharma team — schools, employers, funds. One of them is your warm intro.
Uri Lopatinunlockedknows Mukesh Kumar · together at National Institutes of Health (overlapped)
×2knows the team · via National Institutes of Health
×4knows the team · via Quantic School of Business and Technology
×5knows the team · via Delhi University
ResQ Pharma is a pharmaceutical company developing LipidRescue (LRT), an investigational lipid-based drug therapy that is pending FDA approval. The company works on biologics development, regulatory affairs, and clinical research for its drug candidate.
Founders & leadership
GW
Guy WeinberginDirector, President and Secretary of Issuer
DW
Dr. WeinberginFounder and President
AH
August H. SchuppDirector, CAO and General Counsel of Issuer
DO
Dominic O'KeefeDirector and COO of Issuer
DB
David BowmanExecutive
DM
MS
Mr. SchuppChief Administrative Officer and General Counsel
IR
Israel RubinsteinNamed on SEC filing
Board
PB
JT
Joel TuneIndependent Director of Issuer
PH
Paul HertzBoard director
FW
Francis WisniewskiBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$2.4M disclosed across 5 rounds · 2015–2024
▶$100KraisedDec 2024 · 1 investors · PharmaceuticalsRule 506(b)
▶$100KraisedDec 2024 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- August H. SchuppExecutive Officer, Director, Promoter
- Dominic O'KeefeExecutive Officer, Director, Promoter
- Guy WeinbergExecutive Officer, Director, Promoter
- Joel TuneExecutive Officer, Director, Promoter
- Offering amount
- $100K
- Amount sold
- $100K
- First sale
- Jul 2024
- Incorporated
- Corporation, United States
- Federal exemptions
- 06b
▶$205.5KraisedJun 2022 · 6 investors · PharmaceuticalsRule 506(b)
▶$205.5KraisedJun 2022 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- August H. SchuppExecutive Officer, Director, Promoter
- Joel TuneExecutive Officer, Director, Promoter
- Dominic O'KeefeExecutive Officer, Director, Promoter
- Guy WeinbergExecutive Officer, Director, Promoter
- Offering amount
- $300K
- Amount sold
- $205.5K
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedSep 2020 · 6 investors · PharmaceuticalsRule 506(b)
▶$1MraisedSep 2020 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Steve BylinaExecutive Officer, Director, Promoter
- Francis WisniewskiExecutive Officer, Director, Promoter
- August H. SchuppExecutive Officer, Director, Promoter
- Guy WeinbergExecutive Officer, Director, Promoter
- Antoinette GawinExecutive Officer, Director, Promoter
- Todd BeckExecutive Officer, Director, Promoter
- Paul HertzExecutive Officer, Director, Promoter
- Offering amount
- $2M
- Amount sold
- $1M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$739.5KraisedSep 2016 · 13 investors · PharmaceuticalsRule 506(b)
▶$739.5KraisedSep 2016 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Francis WisniewskiDirector
- Paul BurtonExecutive Officer, Director
- Paul HertzDirector
- Guy WeinbergDirector
- Todd BeckExecutive Officer
- Antoinette GawinDirector
- Offering amount
- $764.5K
- Amount sold
- $739.5K
- Minimum investment
- $9.6K
- First sale
- Aug 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$325KraisedMar 2016 · 8 investors · PharmaceuticalsRule 506(b)
▶$325KraisedMar 2016 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Paul HertzDirector
- Paul BurtonExecutive Officer, Director
- David BowmanExecutive Officer
- Israel RubinsteinDirector
- Francis WisniewskiDirector
- Guy WeinbergDirector
- Offering amount
- $325K
- Amount sold
- $325K
- Minimum investment
- $5K
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapBioQ Pharma13 shared keywordsBioQ Pharma is a pharmaceutical company with expertise in biotech development and healthcare technology. The company appears to be focused on pharmaceutical innovation with a board of directors drawn from senior executives with extensive experience in biotech, medical devices, and pharma commercialization.
STAQ Pharma12 shared keywordsSTAQ Pharma is an FDA-registered 503B outsourcing facility that compounds and supplies medications to hospitals and healthcare providers across the United States, aiming to address drug shortages. The company is owned and guided by several healthcare systems and focuses on safety, transparency, availability, and quality.
SuppCo7 shared keywordsSupp.co is a platform for building, optimizing, and tracking personalized supplement stacks aligned with individual health goals and lifestyles. The company serves health-conscious consumers and biohackers seeking transparency and structure in supplement selection.
Companies competing with ResQ Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does ResQ Pharma do?
- ResQ Pharma is a pharmaceutical company developing LipidRescue (LRT), an investigational lipid-based drug therapy that is pending FDA approval. The company works on biologics development, regulatory affairs, and clinical research for its drug candidate.
- Who founded ResQ Pharma?
- ResQ Pharma was founded by Guy Weinberg, Dr. Weinberg.
- Who are ResQ Pharma's investors?
- ResQ Pharma's investors include 2Flo Ventures.
- How much funding has ResQ Pharma raised?
- ResQ Pharma has disclosed $2.4M raised across 5 rounds.
- Where is ResQ Pharma headquartered?
- ResQ Pharma is headquartered in Glenview, US.